- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 15/16 - Masculine contraceptives
Patent holdings for IPC class A61P 15/16
Total number of patents in this class: 156
10-year publication summary
|
5
|
3
|
7
|
6
|
6
|
15
|
14
|
14
|
6
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bayer Schering Pharma AG | 378 |
6 |
| Kissei Pharmaceutical Co., Ltd. | 183 |
5 |
| Lunella Biotech, Inc. | 105 |
5 |
| Dana-Farber Cancer Institute, Inc. | 2600 |
4 |
| Regents of the University of Minnesota | 2711 |
4 |
| St. Jude Children's Research Hospital | 242 |
4 |
| Contraline, Inc. | 27 |
4 |
| Bayer Pharma AG | 1054 |
3 |
| Abbvie Inc. | 1802 |
3 |
| Memorial Sloan-Kettering Cancer Center | 1960 |
3 |
| University of Newcastle | 14 |
3 |
| University of Pretoria | 122 |
3 |
| Pharmajor International | 4 |
3 |
| Communitreat Ltd. | 3 |
3 |
| Centre National de La Recherche Scientifique | 10576 |
2 |
| Ayumi Pharmaceutical Corporation | 21 |
2 |
| Baylor College of Medicine | 963 |
2 |
| Board of Regents of The Nevada System of Higher Education, on Behalf of The University of Nevada, Reno | 130 |
2 |
| CSL Limited | 254 |
2 |
| Kent State University | 236 |
2 |
| Other owners | 91 |